Thursday - October 30, 2025
AstraZeneca: Saphnelo Self-Administration Tulip-SC Phase III Trial Meets Primary Endpoint in Patients With Systemic Lupus Erythematosus Based on an Interim Analysis
September 18, 2025
WILMINGTON, Delaware, Sept. 18 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis

Subcutaneous administration of first-in-class biologic SAPHNELO demonstrates statistically significant and clinically meaningful reduction in disease activity

*

Posit . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products